Trials / Terminated
TerminatedNCT04381325
A Study of MSB0254 Injection in Advanced Solid Tumors
Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSB0254 Injection | An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W). An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W). |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2022-06-08
- Completion
- 2022-06-08
- First posted
- 2020-05-08
- Last updated
- 2023-04-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04381325. Inclusion in this directory is not an endorsement.